Business Case Studies, Market Entry Strategies Case Study, Dr. Reddy's Laboratories in Europe, The Inorganic Growth Strategy

print page
Tell A Friend
Bookmark
 

Case Categories

Market Entry Strategies Case Study

IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
Case Title:

Dr. Reddy's Laboratories, the Leading Indian Pharmaceutical Company, in Europe: The Inorganic Growth Strategy

Publication Year : 2006

Authors: Satyakama Paul, Supratim Majumdar

Industry: Health Care

Region:India

Case Code: MES0053K

Teaching Note: Not Available

Structured Assignment: Not Available

Buy This Case Study
OR





Abstract:

In February 2006, the Indian pharmaceutical company, Dr. Reddy’s Laboratories Limited (DRL), announced that it would acquire the Germany’s fourth largest generic pharmaceutical, betapharm. The deal was settled at US$ 570 million. After the US, Europe was the second largest pharma market with Germany as its largest constituent. Moreover, worldwide it was the third largest generic market. The market trends showed that generics had a better market potential over their branded counterparts. In addition, the European generic market proved to be more lucrative than the US market because it had less of governmental rules directed towards drug approvals and marketing.

The case analyses the synergies and possible challenges of such an acquisition and discusses the inorganic growth strategy of DRL that was aimed at penetration into the German and subsequently the European generic market. It also provides a brief overview of the two companies.

Pedagogical Objectives:

  • To discuss DRL’s inorganic strategies by which it aimed to penetrate into the world’s fourth largest generic market, Germany and subsequently the European generic market
  • To discuss the possible synergies and challenges of the acquisition.

Keywords : Dr Reddy's Laboratories; Betapharm; Pharmaceutical industry; Generics; United States Food and Drug Administration (USFDA); Abbreviated new drug application; Paragraph IV filing; Active pharmaceutical ingredients; Patent right; Market Entry Strategies Case Study; Branded drugs; Inorganic growth strategy; First to file; Research and development (R&D)

Contents : 
Introduction
Dr. Reddy’s Laboratories
Betapharm: European Opportunity For Drl
Possible Challenges
The Modus Operandi Of Para Iv Certification
The Valuation Of The Branded Drugs Of Europe
The Size Of The Generic Market

Recently Bought Case Studies

    Recently Bought Case Studies
advertisement

    Executive Interviews

  • David ConklinDavid Conklin

    David Conklin, is a professor at the Richard Ivey School of Business
    Speaks on Government and Business
  • Lord Meghnad DesaiLord Meghnad Desai

    Lord Meghnad Desai, is an Indian-born British economist and Labor politician
    Speaks on Government and Business
  • Vijay GovindarajanVijay Govindarajan

    Vijay Govindarajan, is widely regarded as one of the world’s leading experts on strategy and innovation
    Speaks on Reverse Innovation
  • View All Executive Interviews»






Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-501 504, Andhra Pradesh, INDIA.
Mob: +91- 9640901313, Phone: +91 - 08417 - 236672, Fax : + 91 - 08417 - 236674
E-mail: casehelpdesk@ibsindia.org

©2003-2010 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map xml sitemap